Previous reports have identified ERBB2 and ERBB3 alteration at a frequency of 6.5%–11.5% in CRC (23, 24), whereas 23.8% of patients with mCRC exhibited alterations in ERBB2/ERBB3 in our study. This evidence concerns the gene ERBB3 and colorectal carcinoma.